Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

Summary

This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.

Timeline

Start

2022-03-08

Primary completion

2025-03-31

Completion

2025-12

Drugs

Indications